Filing Flows

Filing Flows › Companies › Mereo BioPharma Group › Cash flow

Mereo BioPharma Group cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.0M in Q2 2026 · −$25.3M over twelve months

Operating cash flow−$6.0M
Free cash flow−$6.0M

Analysis

In Q2 2026, Mereo BioPharma Group generated −$6.0M of operating cash flow. That is $1.6M more than in Q2 2025 (−$7.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$25.3M; the largest uses were operating cash flow ($25.3M); besides operations, cash came from other financing ($39K); the cash balance fell by $26.0M.

Operating cash flow was −$6.0M against net income of −$7.0M. The largest differences: payables −$2.1M, stock-based pay +$1.3M, prepaid and other assets +$681K.

Free cash flow

Mereo BioPharma Group: free cash flow by quarterMereo BioPharma Group: free cash flow by quarter−$7.5MQ3 2024−$9.4MQ4 2024−$8.3MQ1 2025−$7.7MQ2 2025−$7.3MQ3 2025−$7.7MQ4 2025−$4.3MQ1 2026−$6.0MQ2 2026
Operating cash flow less capital spending.
Mereo BioPharma Group: operating cash flow against capital spendingMereo BioPharma Group: operating cash flow against capital spendingOperating cash flowCapital spending−$7.5M$0Q3 2024−$9.4M$0Q4 2024−$8.3M$20KQ1 2025−$7.7M$0Q2 2025−$7.3M$0Q3 2025−$7.7M$0Q4 2025−$4.3M$0Q1 2026−$6.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$6.0M, Capital spending $0.

Capital allocation, year by year

Mereo BioPharma Group: where the cash came from (up) and went (down), by fiscal yearMereo BioPharma Group: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2022: Operating cash flow −$48.8MFY2022: Capital spending −$13KFY2022FY2023: Operating cash flow −$21.1MFY2023: Net borrowing −$3.2MFY2023: Shares issued $11.6M$11.6MFY2023FY2024: Operating cash flow −$32.8MFY2024: Shares issued $47.0M$47.0MFY2024FY2025: Operating cash flow −$31.0MFY2025: Shares issued $39KFY2025: Capital spending −$20K$39KFY2025
Over these 4 years operating cash flow totalled −$134M; the largest uses were operating cash flow ($134M) and net borrowing ($3.2M). Cash-flow statements as filed.

Where the cash came from and went

Mereo BioPharma Group: sources (+) and uses (−) of cash, Q2 2026Mereo BioPharma Group: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$6.1MOperating cash flow−$6.0MExchange rates−$62K
Mereo BioPharma Group: sources (+) and uses (−) of cash, TTM to Q2 2026Mereo BioPharma Group: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$26.0MOperating cash flow−$25.3MExchange rates−$700KOther financing$39K

From profit to cash

Mereo BioPharma Group: net income to operating cash flow, Q2 2026Mereo BioPharma Group: net income to operating cash flow, Q2 2026Net income−$7.0MDepreciation & amortization$165KStock-based pay$1.3MPayables−$2.1MAccrued liabilities$577KPrepaid and other assets$681KOperating cash flow−$6.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.0M——$6.1M−$6.0M
Q1 2026−$4.3M——$4.8M−$4.3M
Q4 2025−$7.7M—$39K$7.7M−$7.7M
Q3 2025−$7.3M——$7.4M−$7.3M
Q2 2025−$7.7M——$6.4M−$7.7M
Q1 2025−$8.3M−$20K—$7.3M−$8.3M
Q4 2024−$9.4M——$10.7M−$9.4M
Q3 2024−$7.5M——$6.9M−$7.5M

Mereo BioPharma Group: income statement and cash flow

Mereo BioPharma Group, Q2 2025: revenue $500K. The chart follows the revenue to costs, profit and cash.

Mereo BioPharma Group: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.